

Title (en)
MUCIN-1 DERIVED ANTIGENS AND THEIR USE IN IMMUNOTHERAPY

Title (de)
VON MUCIN-1 ABGELEITETE ANTIGENE UND IHRE VERWENDUNG IN DER IMMUNTHERAPIE

Title (fr)
ANTIGENES DERIVES DE MUCINE-1 ET LEUR UTILISATION EN IMMUNOTHERAPIE

Publication
EP 1257565 A4 20050406 (EN)

Application
EP 01902160 A 20010201

Priority
• AU 0100090 W 20010201
• AU PQ536900 A 20000201
• US 59387000 A 20000614

Abstract (en)
[origin: WO0157068A1] Peptides and polypeptides capable of eliciting the immune response are disclosed which comprise an amino acid sequence substantially corresponding to that of an epitope of the non-VNTR, non-leader region of mucin. The peptides or polypeptides are useful themselves, or in the form of fusion proteins or conjugate compounds with carbohydrate polymers, in the prevention or treatment of disease states, particularly carcinomas such as adenocarcinomas. DNA vaccines and uses of the peptides and polypeptides for pulsing dendritic cells for <i>in vivo</i> transfer are also disclosed.

IPC 1-7
C07K 7/06; **C07K 7/08**; **C07K 14/82**; **C07K 16/32**; **A61K 38/08**; **A61K 39/395**; **A61K 39/44**; **A61P 35/00**

IPC 8 full level
C12N 15/09 (2006.01); **A61K 31/711** (2006.01); **A61K 38/00** (2006.01); **A61K 39/00** (2006.01); **A61P 35/00** (2006.01); **A61P 37/04** (2006.01); **C07K 14/435** (2006.01); **C07K 14/47** (2006.01); **C07K 14/705** (2006.01); **C07K 19/00** (2006.01)

CPC (source: EP US)
A61P 35/00 (2018.01 - EP); **A61P 37/04** (2018.01 - EP); **C07K 14/4727** (2013.01 - EP); **A61K 38/00** (2013.01 - EP); **A61K 39/00** (2013.01 - EP US); **A61K 2039/53** (2013.01 - EP); **C07K 2319/00** (2013.01 - EP)

Citation (search report)
• [PX] WO 0006723 A1 20000210 - YEDA RES & DEV [IL], et al
• [E] WO 0118035 A2 20010315 - TRANSGENE SA [FR], et al
• [X] CARMON L ET AL: "NOVEL BREAST-TUMOR-ASSOCIATED MUC1-DERIVED PEPTIDES: CHARACTERIZATION IN DB-/- X BETA2 MICROGLOBULIN (BETA2M) NULL MICE TRANSGENIC FOR A CHIMERIC HLA-A2.1/DB-BETA2 MICROGLOBULIN SINGLE CHAIN", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 85, no. 3, 2000, pages 391 - 397, XP001009767, ISSN: 0020-7136
• [A] APOSTOLOPOULOS V ET AL: "MUC1 AND BREAST CANCER", CURRENT OPINION IN MOLECULAR THERAPEUTICS, CURRENT DRUGS, LONDON,, GB, vol. 1, no. 1, February 1999 (1999-02-01), pages 98 - 103, XP001097590, ISSN: 1464-8431
• [A] BROSSART P ET AL: "Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies", BLOOD, W.B.SAUNDERS COMPAGNY, ORLANDO, FL, US, vol. 93, no. 12, 15 June 1999 (1999-06-15), pages 4309 - 4317, XP002147432, ISSN: 0006-4971
• [A] VAUGHAN H A ET AL: "Induction of humoral and cellular responses in cynomolgus monkeys immunised with mannan-human MUC1 conjugates", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 17, no. 20-21, 4 June 1999 (1999-06-04), pages 2740 - 2752, XP004169689, ISSN: 0264-410X
• [A] ZRIHAN-LICHT S ET AL: "CHARACTERIZATION AND MOLECULAR CLONING OF A NOVEL MUC1 PROTEIN, DEVOID OF TANDEM REPEATS, EXPRESSED IN HUMAN BREAST CANCER TISSUE", EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 224, no. 2, 1 September 1994 (1994-09-01), pages 787 - 795, XP000575936, ISSN: 0014-2956
• See also references of WO 0157068A1

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)
WO 0157068 A1 20010809; CA 2399026 A1 20010809; EP 1257565 A1 20021120; EP 1257565 A4 20050406; JP 2003533181 A 20031111

DOCDB simple family (application)
AU 0100090 W 20010201; CA 2399026 A 20010201; EP 01902160 A 20010201; JP 2001557899 A 20010201